Table 2: Hematopoietic Recovery and Non-Haematologic Toxicity

N° %
ENGRAFTMENT
  • ANC > 1x109/L, median days (range)
  • PLT > 50x109/L, median days (range)
  • Packed red cells units, median (range)
  • Platelet units, median (range)
  • Hospitalisation, median days (range)
 30/30
18 (12-31)
19 (10-60)
7 (1-30)
4 (1-30)
40 (28-90) 		100
GVHD
  • ACUTE GVHD (N°/evaluable pts)
Grade 1-2
Grade 3-4
  • CHRONIC GVHD (N°/evaluable pts)
Limited
Extensive 		17/30
13/30
4/30
11/22
9/22
2/22 		57
43
14
50
41
9
COMPLICATIONS
  • Mucositis grade III/IV
  • Pneumonia
  • Bacteremia
  • CMV infectious
  • Haemorrage grade III/IV
  • Cardiotoxicity
  • Liver toxicity grade III/IV
  • VOD
 5/30
9/30
14/30
10/30
2/30
5/30
2/30
0/30 		17
30
47
33
6
15
6
0
1 year Overall Survival2 year Disease Free Survival 57%
(95% CI: 24-81%)
35%
(95% CI: 22-82%)

GVHD, graft-versus-host disease; VOD, veno-occlusive disease, CMV, citomegalovirus.